Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Incyte
< Previous
1
2
3
4
Next >
Incyte to Report Second Quarter Financial Results
July 09, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 08, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Completes Acquisition of Escient Pharmaceuticals
May 30, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings
May 21, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conference
May 21, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
May 14, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conference
May 02, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
April 30, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Report First Quarter Financial Results
April 11, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
April 01, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 29, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
March 10, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
March 04, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI
February 29, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
February 27, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conference
February 15, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
February 13, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
February 05, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
January 23, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conferences
December 12, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
November 02, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
October 31, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Science Magazine Recognizes Incyte as #2 “Top Employer” of 2023
October 27, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conferences
October 18, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023
October 16, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
October 13, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Data From Incyte’s Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)
October 13, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients
October 11, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.